Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Immunotherapy × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 47 Hodgkin Disease 25 Lymphoma 13 Sarcoma 7 Skin Neoplasms 6 Neoplasm Metastasis 6 Uveal Melanoma 5 Leiomyosarcoma 5 Neoplasms 4 Solitary Fibrous Tumors 2 Sarcoma, Synovial 2 Solid Tumor 1 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroblastoma 1 Melanoma Neoplasms 1 Liposarcoma 1 Immunotherapy 1 Histiocytoma, Malignant Fibrous 1 Hematologic Diseases 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1

Interventions

tislelizumab 1 apatinib 1 Tegafur 1 Oxaliplatin 1 Dacarbazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04225390 2026-02-10

PROMIT

University of Erlangen-Nürnberg Medical School

Phase 2 Completed

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡